NDLI: Prodrugs in cancer chemotherapy

Content Provider	Springer Nature Link
Author	Kx, Richard J Conrs, Tom A
Copyright Year	1997
Abstract	At present, chemotherapy is not very effective against common solid cancers especially once they have metastasised. However, laboratory experiments and studies on dose intensification in humans have indicated that some anti-cancer agents might be curative but only if the dose given was very much higher than that presently obtainable clinically. Prodrugs, activated by enzymes expressed at raised level in tumors, can deliver at least 50-fold the normal dose and can cure animals with tumors normally resistant to chemotherapy. This approach has not yet proved to be practicable clinically because of the rarity of human tumors expressing a high level of an activating enzyme. However, new therapies have been proposed overcome this limitation of prodrug therapy. Enzymes that activate prodrugs can be directed to human tumor xenografts by conjugating them to tumor associated antibodies. After allowing for the conjugate to clear from the blood a prodrug is administered which is normally inert but which is activated by the enzyme delivered to the tumor. This procedure is referred to as ADEPT (antibody-directed enzyme prodrug therapy). Early clinical trials are promising and indicate that ADEPT may become an effective treatment for all solid cancers for which tumor associated or tumor specific antibodies are known. Tumors have also been targeted with the genes encoding for a prodrug activating enzymes. This approach has been called genedirected enzyme prodrug therapy (GDEPT) or VDEPT (virus-directed enzyme prodrug therapy) and has shown good results in animal models. These new therapies may finally realise the potential of prodrugs in cancer chemotherapy.
Starting Page	309
Ending Page	324
Page Count	16
File Format	PDF
ISSN	12194956
Journal	Pathology & Oncology Research
Volume Number	3
Issue Number	4
e-ISSN	15322807
Language	English
Publisher	Springer Netherlands
Publisher Date	1997-01-01
Publisher Place	Dordrecht
Access Restriction	Subscribed
Subject Keyword	antibody targeting drug targeting gene therapy antitumor agents Cancer Research Oncology Pathology Immunology Biomedicine general
Content Type	Text
Resource Type	Article
Subject	Cancer Research Pathology and Forensic Medicine Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Molecular events as targets of anticancer drug therapy

Embryotoxicity and teratogenicity of some derivatives of chloroethylaminophenylacetic acid

Chemotherapy of oesophago-gastric cancer

Human osteosarcoma xenografts and their sensitivity to chemotherapy

DNA topoisomerase I in oncology: Dr Jekyll or Mr Hyde?

Preoperative Systemic Chemotherapy and Pathologic Assessment of Response

MicroRNA-200c Regulates the Sensitivity of Chemotherapy of Gastric Cancer SGC7901/DDP Cells by Directly Targeting RhoE

Viral therapy of human cancer

Drug resistance in ovarian cancer — the role of p53

Prodrugs in cancer chemotherapy

Similar Documents

Molecular events as targets of anticancer drug therapy

Embryotoxicity and teratogenicity of some derivatives of chloroethylaminophenylacetic acid

Chemotherapy of oesophago-gastric cancer

Human osteosarcoma xenografts and their sensitivity to chemotherapy

DNA topoisomerase I in oncology: Dr Jekyll or Mr Hyde?

Preoperative Systemic Chemotherapy and Pathologic Assessment of Response

MicroRNA-200c Regulates the Sensitivity of Chemotherapy of Gastric Cancer SGC7901/DDP Cells by Directly Targeting RhoE

Viral therapy of human cancer

Drug resistance in ovarian cancer — the role of p53

Prodrugs in cancer chemotherapy